Nuvation Bio (NUVB) Competitors $2.98 +0.10 (+3.40%) Closing price 03:59 PM EasternExtended Trading$2.98 +0.00 (+0.03%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. LNTH, APLS, MLTX, PTGX, MIRM, MENS, MTSR, BHC, KYMR, and SRRKShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Lantheus (LNTH), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), Jyong Biotech (MENS), Metsera (MTSR), Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Its Competitors Lantheus Apellis Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Mirum Pharmaceuticals Jyong Biotech Metsera Bausch Health Cos Kymera Therapeutics Scholar Rock Nuvation Bio (NYSE:NUVB) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations. Which has preferable earnings & valuation, NUVB or LNTH? Lantheus has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M129.51-$567.94M-$0.63-4.73Lantheus$1.53B2.47$312.44M$3.7614.80 Is NUVB or LNTH more profitable? Lantheus has a net margin of 17.82% compared to Nuvation Bio's net margin of -1,413.43%. Lantheus' return on equity of 34.06% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-1,413.43% -46.14% -36.04% Lantheus 17.82%34.06%19.10% Do analysts recommend NUVB or LNTH? Nuvation Bio presently has a consensus price target of $7.33, suggesting a potential upside of 146.25%. Lantheus has a consensus price target of $105.50, suggesting a potential upside of 89.54%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Lantheus 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Do insiders & institutionals have more ownership in NUVB or LNTH? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by company insiders. Comparatively, 2.0% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to NUVB or LNTH? In the previous week, Lantheus had 33 more articles in the media than Nuvation Bio. MarketBeat recorded 35 mentions for Lantheus and 2 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 1.03 beat Lantheus' score of 0.69 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 15 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, NUVB or LNTH? Nuvation Bio has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. SummaryLantheus beats Nuvation Bio on 9 of the 16 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$985.75M$3.07B$5.73B$21.16BDividend YieldN/A2.27%3.95%3.54%P/E Ratio-4.7320.5230.3328.99Price / Sales129.51392.09463.5454.57Price / CashN/A44.2437.7223.61Price / Book2.738.139.775.33Net Income-$567.94M-$54.08M$3.27B$995.89M7 Day Performance10.91%4.92%3.95%2.56%1 Month Performance19.36%3.64%3.81%2.81%1 Year Performance-4.86%8.20%31.26%11.06% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio2.1095 of 5 stars$2.98+3.4%$7.33+146.3%+0.0%$985.75M$7.87M-4.7360Positive NewsLNTHLantheus4.7582 of 5 stars$55.97+3.3%$105.50+88.5%-47.6%$3.68B$1.52B14.89700News CoverageAnalyst RevisionAPLSApellis Pharmaceuticals4.2248 of 5 stars$27.35-1.4%$34.12+24.7%-31.4%$3.50B$781.37M0.00770MLTXMoonLake Immunotherapeutics2.0377 of 5 stars$53.73-1.2%$74.43+38.5%+9.8%$3.49BN/A0.002PTGXProtagonist Therapeutics1.9135 of 5 stars$56.21+0.2%$67.20+19.6%+36.5%$3.49B$434.43M80.10120Positive NewsMIRMMirum Pharmaceuticals3.6026 of 5 stars$66.68-1.8%$74.13+11.2%+74.6%$3.41B$336.89M0.00140News CoveragePositive NewsAnalyst DowngradeMENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.40BN/A0.0031MTSRMetseraN/A$32.39+4.0%$55.00+69.8%N/A$3.27BN/A0.0081News CoveragePositive NewsBHCBausch Health Cos4.5517 of 5 stars$8.02-3.8%$9.00+12.2%+24.4%$3.09B$9.63B30.8520,700Analyst RevisionKYMRKymera Therapeutics2.9848 of 5 stars$43.62+2.3%$59.11+35.5%-12.5%$3.05B$47.07M0.00170SRRKScholar Rock4.5534 of 5 stars$31.52+0.4%$45.14+43.2%+259.5%$3.02B$33.19M-10.83140Positive News Related Companies and Tools Related Companies Lantheus Alternatives Apellis Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Protagonist Therapeutics Alternatives Mirum Pharmaceuticals Alternatives Jyong Biotech Alternatives Metsera Alternatives Bausch Health Cos Alternatives Kymera Therapeutics Alternatives Scholar Rock Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is hereTop analysts are calling the AI boom “an existential race” — and Washington is going all in. Trillions are bei...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access